|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-β1,vascular endothelial growth factor,and basic fibroblast growth factor in patients with chronic hepatitis C显示文摘AIM:To assess the role of transforming growth factor-β1(TGF-β1),vascular endothelial growth factor(VEGF)andbasic fibroblast growth factor(bFGF)in the pathogenesisof fibrosis associated with chronic hepatitis C(CHC)and to evaluate the influence of the antiviral therapyon above parameter levels depending on the treatmentresults(complete response or no response).METHODS:Study group included 100 patients withCHC,in whom fibrosis in liver specimens was assessed(Scheuer fibrosis score:1-4 points).Control groupincluded 30 subjects with antibodies anti-HCV presentand persistently normal ALT level,without fibrosis(Scheuer fibrosis score:0 points).Concentration ofstudied parameters was assayed in the serum byimmunoenzymatic method before and after the therapywith interferon alpha-2b and ribavirin.RESULTS:TGF-β1 levels were significantly higher in thestudy group compared to the control group(35.89 vs 32.37ng/mL;P=0.023).Such differences were not found in VEGFand bFGF levels.In patients showing complete response(negative HCV RNA and normal ALT level),significantincrease in VEGF(112.8 vs 315.03 pg/mL;P<0.05)andbFGF(2.51 vs 15.79 pg/mL;P=0.04)levels were found.Significant decrease in TGF-β1 level was observed bothin responders(37.44 vs 30.02 ng/mL;P=0.05),andin non-responders(38.22 vs 30.43 ng/mL;P=0.043).bFGF levels before the treatment were significantly lower(2.51 vs 5.94 pg/mL;P=0.04),and after the treatmentsignificantly higher(15.79 vs 4.35 pg/mL;P=0.01) in patients with complete response than in those with noresponse.CONCLUSION:Among the analyzed parametersTGF-β1 seems to play the most important role in thepathogenesis of fibrosis in CHC.Levels of this factor aresignificantly lower in subjects who do not have fibrosisdeveloped in them.Good therapeutic effect in CHCpatients is associated with significant changes in TGF-β1,VEGF,and bFGF levels,bFGF seems to have the highestusefulness in the prognosis of treatment efficacy. | Ewa Janczewska-Kazek Bogdan Marek Dariusz Kajdaniuk Halina BorgieI-Marek | 2006 | World Journal of Gastroenterology2006，12，6： | 5 |
| 2 | Quantitative assessment of mRNA TGF - beta 1 in liver tissue in connection with serum mean daily level of TGF - 1 in chronc hepatitis B patient 显示文摘 | MAREK B KAJDANIUK D MAZUREK U | 2005 | Pol Arch Med Wewn2005，114，2： | 1 |
| 3 | Adiponectin, leptin, resistin and insulin blood concentrations in patients with ischaemic cerebral stroke显示文摘 | Bienek R Marek B Kajdaniuk D | 2012 | Endokrynol Pol2012，63，5： | 1 |
| 4 | Vascular endothelial growth factor(VEGF)-part 1:in physiology and pathophysiology显示文摘 | Kajdaniuk D Marek B Foltyn W | 2011 | Endokrynol Pol2011，62，5： | 1 |
| 5 | Transforming growth factor betal ( TGFbetal ) in physiology and pathology 显示文摘 | Kajdaniuk D Marek B Borgiel-Marek H | 2013 | Endokrynol Pol2013，64，5： | 1 |
| 6 | Wernicke- Korsakoff syndrome in the course of thyrotoxicosis - a case report显示文摘 | Wierzbicka-Chmiel J Wierzbicki K Kajdaniuk D | 2011 | Endokrynol Pol2011，62，： | 1 |
| 7 | Is positive correla-tion between cortisol and met-enkephalin concentration in blood of women with breast cancer a reaction to stress before chemotherapy administration显示文摘 | Kajdaniuk D Marek B Swietochowska E | 2000 | Pathophysiology2000，7，1： | 1 |
| 8 | Vascular endothe- lial growth factor (VEGF)--part 1 :in physiology and pathophysi- ology显示文摘 | Kajdaniuk D Marek B Borgiel-Marek H | 2011 | Endokrynologia Polska2011，62，5： | 1 |
| 9 | Vascular endothelial growth factor (VEGF)-part 2: in endocrinology and oncology显示文摘 | Kajdaniuk D Marek B Foltyn W | 2011 | Endokrynol Pol2011，62，： | 1 |
| 10 | Vascular endothelial growth factor (VEGF)-part 1:in physiology and pathophysiology显示文摘 | Kajdaniuk D Marek B Borgiel-Marek H | 2011 | Endokrynol Pol2011，62，5： | 1 |
| 11 | Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology显示文摘 | Kajdaniuk D Marek B Borgiel-Marek H | 2011 | Endokrynol eol2011，62，5： | 1 |
| 12 | Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology 显示文摘 | KAJDANIUK D MAREK B FOLTYN W | 2011 | Endokrynol Pol2011，62，5： | 1 |
| 13 | Vascular endo-thelial growth factor (VEGF)-part 1: in physiology and patho-physiology显示文摘 | Kajdaniuk D Marek B Borgiel-Marek H | 2011 | Endokrynol Pol2011，62，5： | 1 |
| 14 | Vascular endothelial growth factor (VEGF)-part 1:in physiology and pathophysiology显示文摘 | Kajdaniuk D Marek B Foltyn W | | 0，，： | 1 |
| 15 | Transforming growth factor 131 (TGF - 131 ) in physiology and pathology显示文摘 | Kajdaniuk D Marek B Borgiel - Marek H | 2013 | En- dokrynol Pol2013，64，5： | 1 |
| 16 | Transforming growth factor beta1(TGFbeta1)in physiology and pathology显示文摘 | Kajdaniuk D Marek B Borgiel-Marek H | 2013 | Endokrynologia Polska2013，64，5： | 1 |
| 17 | Vascular endothelial growth factor (VEGF)-part I : in physiology and pathophysiology 显示文摘 | KAJDANIUK D MAREK B BORGIEL-MAREK H | 2011 | Endokrynologia Polska2011，62，5： | 1 |
| 18 | Vascular endothelial growth factor (VEGF) - part I: in physiology and pathophysiology显示文摘 | Kajdaniuk D Marek 8 Foltyn W | 2011 | Endokrynol Pol2011，62，5： | 1 |
| 19 | Vascular endothelial growth factor(VEGF) in endocrinology and oncology显示文摘 | Kajdaniuk D Marek B Foltyn W | 2011 | En- dokrynol Pol2011，62，3： | 1 |
| 20 | Trans-forming growth factor betal (TGFbetal) in physiology and pa-thology 显示文摘 | KAJDANIUK D MAREK B BORG旧L-MAREK H | 2013 | Endokrynol Pol2013，64，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员